Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. We describe immune-modified RECIST (imRECIST) criteria, designed to...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of clinical oncology Ročník 36; číslo 9; s. 850
Hlavní autori:	Hodi, F Stephen, Ballinger, Marcus, Lyons, Benjamin, Soria, Jean-Charles, Nishino, Mizuki, Tabernero, Josep, Powles, Thomas, Smith, David, Hoos, Axel, McKenna, Chris, Beyer, Ulrich, Rhee, Ina, Fine, Gregg, Winslow, Nathan, Chen, Daniel S, Wolchok, Jedd D
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 20.03.2018
Predmet:	Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - immunology Carcinoma, Non-Small-Cell Lung - therapy Carcinoma, Renal Cell - immunology Carcinoma, Renal Cell - therapy Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Humans Immunotherapy - methods Kidney Neoplasms - immunology Kidney Neoplasms - therapy Lung Neoplasms - immunology Lung Neoplasms - therapy Melanoma - immunology Melanoma - therapy Neoplasms - immunology Neoplasms - therapy Progression-Free Survival Urologic Neoplasms - immunology Urologic Neoplasms - therapy
ISSN:	1527-7755, 1527-7755
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!